Table 3.
Comparison of demographics and clinicopathologic characteristics of patients with epitheloid MPM and low or high gC1qR expression in no neoadjuvant chemotherapy (no-NAC) and neoadjuvant chemotherapy (NAC) cohorts.
| Cohort | No-NAC | NAC | |||||
|---|---|---|---|---|---|---|---|
| gC1qR | Low (<151) | High (≥151) | Low (<166) | High (≥166) | |||
| N = 78 | N = 79 | P | N = 29 | N = 30 | P | ||
| Age | 62 (55–68) | 65 (56–73) | 0.084 | 58 (52–67) | 59 (47–67) | 0.7 | |
| Gender | Female | 26 (33) | 19 (24) | 0.2 | 6 (21) | 12 (40) | 0.2 |
| Male | 52 (67) | 60 (76) | 23 (79) | 18 (60) | |||
| Smoking status (n = 167) | (–) | 12 (26) | 16 (25) | 1.0 | 8 (29) | 8 (28) | 1.0 |
| (+) | 35 (74) | 47 (75) | 20 (71) | 21 (72) | |||
| Asbestos (n = 154) | (–) | 18 (43) | 19 (32) | 0.3 | 15 (56) | 13 (50) | 0.8 |
| (+) | 24 (57) | 40 (68) | 12 (44) | 13 (50) | |||
| Procedure | EPP | 38 (49) | 47 (59) | 0.3 | 17 (59) | 21 (70) | 0.5 |
| PD | 34 (44) | 29 (37) | 11 (38) | 7 (23) | |||
| Other | 6 (8) | 3 (4) | 1 (3) | 2 (7) | |||
| R status (n = 205) | R1 | 58 (78) | 68 (89) | 0.077 | 24 (86) | 24 (89) | 1.0 |
| R2 | 16 (22) | 8 (11) | 4 (14) | 3 (11) | |||
| p-Stage | I | 1 (1) | 5 (6) | 0.040 | 4 (14) | 0 (0) | 0.078 |
| II | 14 (18) | 26 (33) | 8 (28) | 11 (37) | |||
| III | 53 (68) | 40 (51) | 13 (45) | 18 (60) | |||
| IV | 10 (13) | 8 (10) | 4 (14) | 1 (3) | |||
| T category (n = 215) | T1 | 2 (3) | 8 (10) | 0.005 | 4 (14) | 0 (0) | 0.075 |
| T2 | 27 (35) | 42 (54) | 11 (38) | 15 (50) | |||
| T3 | 42 (54) | 23 (29) | 10 (34) | 14 (47) | |||
| T4 | 7 (9) | 5 (6) | 4 (14) | 1 (3) | |||
| N category (n = 212) | N0 | 49 (64) | 55 (71) | 0.5 | 24 (83) | 22 (79) | 0.9 |
| N1 | 9 (12) | 5 (6) | 0 | 1 (4) | |||
| N2 | 19 (25) | 18 (23) | 5 (17) | 5 (18) | |||
| Pleomorphic morphology | (–) | 65 (83) | 68 (86) | 0.7 | 23 (79) | 25 (83) | 0.7 |
| (+) | 13 (17) | 11 (14) | 6 (21) | 5 (17) | |||
| Lymphatic invasion (n = 215) | (–) | 41 (53) | 37 (47) | 0.6 | 16 (55) | 13 (43) | 0.4 |
| (+) | 37 (47) | 41 (53) | 13 (45) | 17 (57) | |||
| Vascular invasion (n = 215) | (–) | 58 (74) | 60 (77) | 0.9 | 25 (86) | 19 (63) | 0.072 |
| (+) | 20 (26) | 18 (23) | 4 (14) | 11 (37) | |||
| CD3+ T cells (n = 212) | Low | 30 (39) | 37 (47) | 0.3 | 16 (55) | 13 (45) | 0.6 |
| High | 46 (61) | 41 (53) | 13 (45) | 16 (55) | |||
| CD4+ T cells (n = 213) | Low | 33 (43) | 38 (49) | 0.5 | 14 (48) | 15 (52) | 1.0 |
| High | 44 (57) | 40 (51) | 15 (52) | 14 (48) | |||
| CD8+ T cells (n = 213) | Low | 38 (49) | 39 (50) | 1.0 | 14 (48) | 14 (48) | 1.0 |
| High | 39 (51) | 39 (50) | 15 (52) | 15 (52) | |||
| FoxP3+ T cells (n = 209) | Low | 35 (47) | 38 (49) | 0.9 | 11 (41) | 18 (62) | 0.2 |
| High | 40 (53) | 40 (51) | 16 (59) | 11 (38) | |||
| CD20+ B cells (n = 212) | Low | 36 (47) | 37 (47) | 1.0 | 16 (55) | 13 (45) | 0.6 |
| High | 40 (53) | 41 (53) | 13 (45) | 16 (55) | |||
| CD68+ macrophages (n = 212) | Low | 35 (45) | 35 (45) | 1.0 | 14 (52) | 11 (37) | 0.3 |
| High | 42 (55) | 43 (55) | 13 (48) | 19 (63) | |||
| CD163+ macrophages (n = 208) | Low | 37 (49) | 37 (47) | 1.0 | 13 (50) | 12 (43) | 0.8 |
| High | 39 (51) | 41 (53) | 13 (50) | 16 (57) | |||
| Ki-67 (n = 212) | Low | 41 (53) | 36 (47) | 0.5 | 13 (45) | 15 (54) | 0.6 |
| High | 37 (47) | 41 (53) | 16 (55) | 13 (46) | |||
Data are number (%) or median (25 and 75 percentiles). NAC, neoadjuvant chemotherapy; EPP, extrapleural pneumonectomy; PD, pleurectomy/decortication; gC1qR, globular heads of the C1q receptor; Foxp3, forkhead box P3. Bold values indicate significant p-value.